Navigate Fool.com
Will GILD beat
the market?

Gilead Sciences (NASDAQ: GILD)

Community Rating: 4 Stars: Favorite

89.54 -1.00 (-1.10%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $90.68
Previous Close $90.54
Daily Range $89.83 - $90.78
52-Week Range $55.96 - $92.97
Market Cap $137.5B
P/E Ratio 19.39
Dividend (Yield) $0.00 (0.0%)
Volume 1,523,792
Average Daily Volume 11,458,376
Current FY EPS $6.21

How do you think GILD
will perform against the market?

Top GILD Bull/Bear Pitches


manirg (< 20)
Submitted June 14, 2013

leader in AIDS treatment

0 Replies Reply Report this Post

stockfreak1 (18.29)
Submitted July 24, 2010

With more and more HIV generics around the corner it's not surprising why the CEO is selling and selling quick. Anyone actually see the retail prices on their drugs? Good God Viread is like $12 a pill … More

1 Replies Reply Report this Post

News & Commentary Rss Feed

Why Gilead Stock's Newest Drug Approval Isn't a Gamechanger

Gilead gains FDA approvela for its first cancer drug Zydelig, which will compete against Johnson & Johnson and Pharmacyclics' Imbruvica.

Who Bucked the Trend Among the 5 Most Heavily Shorted Nasdaq Stocks?

Why Gilead Sciences, inc. Stock Was Flat Today

But Gilead Sciences turned in a great quarter. Here's why.

3 Crucial Quotes From Gilead Sciences Stock

Here are three quotes from Gilead Sciences (GILD) management that offer clues as to whether the companies hepatitis C and HIV drug sales will grow through year end.

What Gilead Stock's Latest Blockbuster Approval Means for Investors

Gilead Science's (GILD) Zydelig won approval for use in chronic lymphocytic leukemia, follicular lymphoma, and small lymphocytic lymphoma.

3 Game-Changing Stories That Shook Investors: Inovio Pharmaceuticals, Gilead Sciences, and GlaxoSmit

The health care sector saw a flurry of major news yesterday. Here are three key stories that investors may have missed.

U.S. stocks: Futures up as Ford, Facebook rise premarket

Gilead Stock's Great Expectations and Giant Opportunity

Gilead Sciences raked in a massive $3.48 billion from its wonder drug Sovaldi, trouncing Q2 consensus estimates. So why did this stock drop?.

Gilead Sciences Crushes Second-Quarter Earnings

Gilead's new hepatitis C drug, Sovaldi, helps propels a gigantic earnings beat in the second quarter.

Is Gilead About to Crush Pharmacyclics Stock?

Gilead (GILD) won approval for Zydelig this week as a treatment for chronic lymphocytic leukemia, but that doesn't mean that Johnson & Johnson (JNJ) and Pharmacyclics' Imbruvica is heading for the dustbin.

See More GILD News...





Gilead Sciences (GILD) Description

Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide. Website: http://www.gilead.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks